BC Extra | Jan 17, 2020
Tools & Techniques

EPO decision strengthens UC’s CRISPR patent position in Europe as Editas looks to Cas9 alternatives

A decision at the European Patent Office has confirmed that the CRISPR IP landscape is going to look much different in Europe than it does in the U.S., contributing to the growing complexity of global...
BC Extra | Dec 11, 2019
Tools & Techniques

Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could be more effective...
BC Extra | Oct 7, 2019
Company News

Oct. 7 Company Quick Takes: Editas-MaxCyte, Goldfinch-Takeda, Prometheus-Takeda, DBV and Galderma

Editas licenses MaxCyte tech to develop engineered cell medicines  Editas Medicine Inc. (NASDAQ:EDIT) licensed non-exclusive clinical and commercial rights to Flow Electroporation technology and ExPERT instruments from MaxCyte Inc. (LSE:MXCT) to develop engineered cell medicines,...
Items per page:
1 - 3 of 3